Adagio Therapeutics website screenshot

Adagio Therapeutics

Adagio Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 to discover, develop, and commercialize antibody-based therapies for serious infectious diseases, with an initial focus on SARS-CoV-2 and other respiratory viruses. Its lead programs centered on monoclonal antibody candidates engineered for high potency and broad, evolution-resistant neutralization. The company was renamed Invivyd, Inc. in 2023 (Nasdaq: IVVD) and now advances antibody medicines such as PEMGARDA and the VYD2311 candidate. It was surfaced as a portfolio company of GV (Google Ventures) and added to the API Evangelist network. As a life-sciences therapeutics company it publishes no public developer API, SDK, or documentation surface; this profile captures corporate identity and policy links only.

Adagio Therapeutics is profiled on the APIs.io network. Tagged areas include Company, Life Sciences, Biotechnology, Pharmaceuticals, and Antibody Therapeutics.

🌐 Visit website 📡 Source on GitHub
13.9/100 minimal ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5
0 APIs
CompanyLife SciencesBiotechnologyPharmaceuticalsAntibody TherapeuticsInfectious Diseases

Kin Score

Kin Score Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5
Composite quality — 13.9/100 · minimal
Contract Quality 0.0 / 25
Developer Ergonomics 0.0 / 20
Commercial Clarity 4.2 / 20
Operational Transparency 0.0 / 13
Governance 0.0 / 12
Discoverability 6.8 / 10
Agent readiness — 0/100 · human only
Machine-Readable Contract 0 / 18
Agentic Access Contract 0 / 15
MCP Server 0 / 12
Machine-Readable Auth 0 / 10
Idempotency 0 / 9
Stable Error Semantics 0 / 8
Request/Response Examples 0 / 7
Rate-Limit Signaling 0 / 7
Typed Event Surface 0 / 6
Agent Skills 0 / 5
Well-Known Catalog 0 / 4
Consent & Bot Identity 0 / 3
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/adagio-therapeutics: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Adagio Therapeutics Domain Security

TLSv1.3 · HSTS · DMARC

SECURITY

Resources

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity
DomainSecurity

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService
TermsOfService
 PrivacyPolicy
PrivacyPolicy

Company 2

The organization behind the API

Website
Website
 InvestorRelations
InvestorRelations

Source (apis.yml)

apis.yml Raw ↑ 
aid: adagio-therapeutics
accessModel:
  pricing: unknown
  onboarding: unknown
  trial: false
  try_now: false
  public: false
  label: Unknown
  confidence: low
  source: []
  generated: '2026-07-22'
  method: derived
image: https://kinlane-images.s3.amazonaws.com/shared/apis-json/icons/adagio-therapeutics.png
name: Adagio Therapeutics
description: 'Adagio Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 to discover, develop, and
  commercialize antibody-based therapies for serious infectious diseases, with an initial focus on SARS-CoV-2 and other respiratory
  viruses. Its lead programs centered on monoclonal antibody candidates engineered for high potency and broad, evolution-resistant
  neutralization. The company was renamed Invivyd, Inc. in 2023 (Nasdaq: IVVD) and now advances antibody medicines such as
  PEMGARDA and the VYD2311 candidate. It was surfaced as a portfolio company of GV (Google Ventures) and added to the API
  Evangelist network. As a life-sciences therapeutics company it publishes no public developer API, SDK, or documentation
  surface; this profile captures corporate identity and policy links only.'
url: https://raw.githubusercontent.com/api-evangelist/adagio-therapeutics/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- gv
x-tier: stub
x-tier-reason: portfolio-lead
x-former-name: Adagio Therapeutics
x-current-name: Invivyd, Inc.
x-no-api-surface: true
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-17'
tags:
- Company
- Life Sciences
- Biotechnology
- Pharmaceuticals
- Antibody Therapeutics
- Infectious Diseases
apis: []
common:
- type: DomainSecurity
  url: security/adagio-therapeutics-domain-security.yml
- type: Website
  url: https://www.invivyd.com
- type: InvestorRelations
  url: https://investors.invivyd.com/
- type: TermsOfService
  url: https://www.invivyd.com/terms/
- type: PrivacyPolicy
  url: https://www.invivyd.com/privacy/
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence